Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.520 -0.010 (-0.28%)
Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in September Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML 
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Participate in February Investor Conferences
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
From ADC Therapeutics SA
Via Business Wire
News headline image
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
News headline image
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.